BRCA1 or BRCA2 (BRCA)-deficient tumor cells have defects in DNA double strand break repair by homologous recombination (HR) and fork protection (FP) that are thought to underlie the sensitivity to poly(ADP-ribose) polymerase inhibitor (PARPi). Given the recent finding that PARPi accelerates DNA replication, it was proposed that high speed DNA replication leads to DNA double strand breaks (DSBs). Here, we tested the alternative hypothesis that PARPi sensitivity in BRCA deficient cells results from combined replication dysfunction that causes a lethal accumulation of replication-associated single-stranded DNA (ssDNA) gaps. In support of a gap toxicity threshold, PARPi-induced ssDNA gaps accumulate more excessively in BRCA deficient cells and are suppressed in de novo and genetic models of PARPi resistance while defects in HR or FP often lack this correlation.
INTRODUCTION
BRCA1-and BRCA2-deficient cancer cells have a synthetic lethal interaction with PARP inhibition (Bryant et al., 2005; Farmer et al., 2005) . This landmark finding has led to the use of several PARP inhibitors (PARPi) in the clinic to treat BRCA deficient and other cancers (Ashworth and Lord, 2018; Lord et al., 2014; Mirza et al., 2018) . The synthetic lethality is understood to derive from PARPi inducing DNA double strand breaks (DSBs) that persist in BRCA deficient cells due to defects in homologous recombination (HR) (Bryant et al., 2005; Farmer et al., 2005) and fork protection (FP) (Schlacher et al., (Figure 1A,B) . Consistent with recent observations, our DNA fiber analysis revealed that following 2-h PARPi treatment, both control and the BRCA1 K/O RPE1 cells displayed longer dual labeled replication tracts (5-Iodo-2'-deoxyuridine (IdU) and 5-chloro-2'-deoxyuridine (CldU)) as compared to untreated (Maya-Mendoza et al., 2018) (Figure 1C) . Moreover, we confirmed that BRCA1 deficiency lead to greater fork asymmetry that was reduced with PARPi (Maya-Mendoza et al., 2018) (Figure S1A) .
Strikingly, BRCA1 K/O cells had longer dual labelled tracks as compared to control cells (Figure 1C) indicating that PARPi sensitivity could correlate with an immediate response of longer or accelerated replication tracts.
To test the hypothesis that gaps form in the vicinity of the accelerated replication fork, following PARPi treatment, cells were incubated with the S1 nuclease that digests ssDNA regions (Quinet et al., 2017; Quinet et al., 2016) . If nascent ssDNA regions are within the labelled replication tracts, S1 nuclease will cut and therefore, shorten the visible CldU replication tract. Following PARPi treatment, labelled nascent DNA tracks appeared shorter for both control and BRCA1 K/O cells when treated with the nuclease (Figure 1D) . Given that PARPi induces longer initial tract lengths in the BRCA1 deficient cells as compared to control, the similar reduction of tracts lengths following S1 nuclease treatment indicates that PARPi generates a more extensive region of gaps in the BRCA1 K/O cells. To further query the relationship of gaps to individual replication assemblies, we utilized single-molecule localization microscopy (STORM) for direct visualization and quantification of individual replisomes (EdU, MCM6 and PCNA positive sites) and ssDNA bound RPA in the osteosarcoma cell line U2OS (Figure S1B) .
To measure the amounts of incorporated RPA within individual replication domains, we preformed unbiased correlation-based image analyses in control and BRCA1 depleted U2OS cells following PARPi treatment ( Figure 1E) . As compared to the control, the average RPA fork density was greater in the BRCA1 deficient U2OS cells following PARPi treatment (Figure 1F) . Remarkably, nondenaturing immunofluorescence also revealed that PARPi induced ssDNA gaps genome-wide that were also significantly escalated in BRCA K/O RPE1 cells (Figure 1G) . Collectively, these findings indicate that PARPi treatment induces gaps that are more pronounced in PARPi sensitive BRCA1 deficient cells.
Fork acceleration alone does not underlie synthetic lethality caused by PARPi
We previously found that unrestrained replication and gaps caused by loss of the fork remodeler, HLTF were dependent on the BRCA1-associated helicase FANCJ (BACH1/BRIP1), which similar to BRCA1 is a hereditary breast/ovarian cancer and Fanconi anemia gene functioning in HR and FP (Peng et al., 2018) , (Cantor et al., 2004; Levitus et al., 2005; Levran et al., 2005; Litman et al., 2005; Nath et al., 2017; Peng et al., 2018; Peng et al., 2006; Sawyer et al., 2015; Suhasini et al., 2013) . Similar to BRCA1 K/O cells, we observed that FANCJ K/O cells were sensitive to cisplatin or camptothecin, CPT and maintained similar tracts lengths in unchallenged conditions (Figure 1B,1C, S1C) . However, in contrast to BRCA1 K/O cells, following PARPi treatment, FANCJ K/O cells did not display PARPi sensitivity, fork acceleration, undergo S1 nuclease cutting, develop RPA rich fork regions or have genomic ssDNA accumulation (Figure 1C-G, S1D,E) . Given control cells show acceleration and gaps at 10µM PARPi, there could be a gap toxicity threshold that is exceeded in BRCA deficient cells based on a gap ratio ( Figure 1G,H) . However, given that FANCJ is required for PARPi-induced replication acceleration and gaps, either or both could underlie PARPi sensitivity.
To address the role of acceleration and/or gaps in therapy response, we sought to uncouple them. One way to accelerate replication is to deplete the cell cycle regulator, p21 that when combined with PARPi, generates very long replication tracts (Maya-Mendoza et al., 2018) (Figure 2A-D) . Notably, the lengthening of tracts in p21 depleted U2OS or RPE1 cells did not enhance PARPi sensitivity (Figure   2E, 2F) . Furthermore, gaps were significantly decreased (Figure 2G, 2H) . These findings suggest that enhanced fork speed alone is not the cause of PARPi sensitivity (Figure 2I ).
Gap suppression in de novo models of PARPi resistance
If gaps underlie therapy response, then gap suppression should trigger PARPi resistance ( Figure 3A) .
To determine whether gap suppression occurs in models of PARPi resistance, we analyzed cell lines that were initially sensitive to PARPi and then had gained PARPi resistance while propagated in tissue culture (Yazinski et al., 2017) . We first analyzed BRCA1-deficient mouse ovarian tumor cell line, BR5 and its derived PARPi-resistant cell line, BR5-R1(Yazinski et al., 2017) . We confirmed PARPi sensitivity of BR5 as compared to BR5-R1 and BRCA1 proficient T2 cells (Yazinski et al., 2017) (Figure 3B ). We observed that PARPi treatment induced greater replication tract lengthening and gap induction in BRCA1 deficient BR5 cells as compared to BRCA1 proficient T2 cells (Figure 3C) . In contrast, PARPi resistant BR5-R1 cells did not gain longer tracts and PARPi induced gaps were modest unless cotreated with the ATR inhibitor (ATRi), VE-821, that re-establishes PARPi sensitivity (Yazinski et al., 2017) (Figure 3B-D, S2A) . De novo PARPi resistance is also associated with BRCA reversion mutations that restore function (Figure S2B ). In the BRCA2 reversion cell clone C4-2 that derived from the parental BRCA2 mutant PEO1 ovarian cancer cell line (Sakai et al., 2009) , we observed restored fork restraint and gap suppression (Figure S2C,D) indicating that gap suppression (GS), HR and/or FP could confer PARPi resistance.
Next, we analyzed patient derived xenograft (PDX) that while initially sensitive to PARPi, gained resistance while propagated upon serial passage in mice. Tumor samples that were PARPi sensitive showed significant PARPi-induced lengthening of replication tracts (Figure 3E) . Consistent with this lengthening reflecting replication with gaps, elongated tracts dramatically shortened upon S1-nuclease treatment ( Figure 3E) . In contrast, PARPi resistant tumor samples did not show PARPi-induced lengthening or S1 nuclease shortening (Figure 3E) , indicating that gaps were not present. Collectively, these models of acquired PARPi resistance demonstrate a block to PARPi-induced acceleration that causes gaps.
Gaps correlate with PARPi response better than HR or FP status
To further consider the relationship between gaps and PARPi response, we analyzed several wellestablished genetic models of PARPi resistance associated with or without HR and/or FP. In particular, HR and PARPi resistance are re-established in BRCA1 deficient cells by loss of the DNA repair protein 53BP1, which limits HR by blocking DNA end resection (Bouwman et al., 2010; Bunting et al., 2010) .
We confirmed that 53BP1 deletion in BRCA1 K/O RPE1 cells or 53BP1 depletion in BRCA1 deficient BR5 cells enhances PARPi resistance (Noordermeer et al., 2018) (Figure 4A,B and S3A,B) . As compared to BRCA1 deficiency alone, loss of both BRCA1 and 53BP1 reduced PARPi-induced gaps (Figure 4C, S3C ), suggesting that 53BP1 loss restores not only HR, but also suppresses gaps.
PARPi resistance is also re-established in BRCA2 mutant cells with or without FP. In particular, complementation of the BRCA2 mutant Chinese hamster cells, V-C8 with the C-terminal BRCA2 S3291A mutant that is defective in FP restores PARPi resistance similar to BRCA2 wild-type ( Figure   4D ,E) (Schlacher et al., 2011) . Moreover, we observed that both PARPi resistant cell lines had significantly fewer gaps than the vector complemented PARPi sensitive V-C8 cells (Figure 4F ), suggesting that resistance stemmed from gaps being suppressed below a toxicity threshold. In BRCA2 deficient cells, therapy resistance and FP are also enhanced by depletion of the chromatin remodeler, CHD4 (Guillemette et al., 2015; Ray Chaudhuri et al., 2016) Notably, CHD4 depletion not only enhanced PARPi resistance, but also dramatically suppressed PARPi-induced gaps as compared to control (Figure 4G-I ). Based on these described models, it remains unclear if GS, HR or FP underlie the mechanism of PARPi resistance (Figure 4J) . Moreover, in FANCJ null cells without gaps, and defective HR and FP (Peng et al., 2018) , (Cantor et al., 2004; Levitus et al., 2005; Levran et al., 2005; Litman et al., 2005; Nath et al., 2017; Peng et al., 2018; Peng et al., 2006; Sawyer et al., 2015; Suhasini et al., 2013) , it is possible that PARPi resistance reflects residual HR or FP activity.
To better understand the link between gaps and therapy response without the HR and FP confounding the interpretation of resistance mechanism, we flipped the model system to one in which despite HR and/or FP proficiency, cells remain PARPi sensitive allowing one to address if gaps remain ( Figure   5A ). HR is intact in the Fanconi anemia (FA) patient fibroblast cell line that has one wild-type and one mutant (T131P) RAD51 allele, but they remain therapy sensitive (Wang et al., 2015) as we confirmed as compared to a CRISPR corrected line ( Figure 5B) . While PARPi-induced gaps were observed in both wild-type and mutant cells, the mutant cell line had a higher level of gap induction and ratio of gaps ( Figure 5C) . Conceivably, the FP defect in the FA cells could generate DSBs that overwhelm HR and sensitize to PARPi. FP can be restored in the RAD51 mutant FA cells by depletion of the RAD51 negative regulator, RADX(Bhat et al., 2018) . Notably, despite restored FP upon RADX depletion, the RAD51 mutant FA cells remained PARPi sensitive ( Figure 5D ,E and S3D). Because PARPi gaps are observed and the gap ratio was elevated (Figure 5F) , these findings suggest that HR and/or FP are insufficient for PARPi resistance when gaps exceed a toxicity threshold.
DISSCUSSION
PARP1 function and loss-of-function has been linked to ssDNA (Leppard et al., 2003; Lonskaya et al., 2005; Maya-Mendoza et al., 2018; Ray Chaudhuri and Nussenzweig, 2017) . However, ssDNA has been overlooked as the sensitizing lesion in BRCA deficient cells in favor of DNA double stranded breaks. Challenging this break-induced model of therapy sensitivity, PARPi do not initially generate DNA breaks or pause DNA replication forks. Instead, PARPi dysregulates DNA replication as fork reversal and restraint are disrupted (Berti et al., 2013; Maya-Mendoza et al., 2018; Ray Chaudhuri et al., 2012; Sugimura et al., 2008; Zellweger et al., 2015) . Therefore, the mechanism of action of PARPiinduced killing of BRCA deficient cells was in question. As clinical interventions for PARPi resistance are lacking, understanding the sensitizing lesion is of critical importance.
Here, we provide evidence that PARPi leads to dysregulated replication with the induction of ssDNA gaps that accumulate more excessively in BRCA deficient immortalized cells, human and mouse cancer cell lines, and patient tumors. Moreover, PARPi-induced gaps are restricted in FANCJ deficient cells that are not sensitive to PARPi. In BRCA1 deficient cells, PARPi-induced gaps are suppressed in both de novo and genetic models of PARPi resistance. Further indicating gaps as the sensitizing lesion, models of restored or defective HR or FP reveal that despite differences in proficiency, sensitivity correlated with gap induction and resistance with gap suppression (Figure 5G ). Our data also highlight that dysregulated or accelerated replication is not the cause of PARPi sensitivity. Together, these findings reveal that gaps as opposed to loss of HR or FP proficiency more directly predicts PARPi response ( Table 1) .
Rather our findings indicate that toxicity results from gaps that exceed a safe threshold. We envision that the toxicity threshold is more readily exceeded in BRCA deficient cells due to intrinsic defects in coordinating RAD51 replication restraint and gap avoidance functions ((Hashimoto et al., 2010; Kolinjivadi et al., 2017b; Zellweger et al., 2015) ). Indeed, we demonstrate that in response to a range of drugs including cisplatin, BRCA deficiency interferes with replication restraint and gaps develop (Panzarino et al., 2019) . Thus, we propose that HR deficiency is not the root cause of therapy response or for that matter "BRCAness", but rather gaps are the key factor.
In cells defective in restraining replication in response to stress, PARPi treatment could lead to unrestrained replication that proceeds until forks confront PARP-trapped proteins or other intrinsic obstacles that physically block the pre-existing replication fork. Gaps could form as replication reinitiates ahead of the block by re-priming replication. The extensive regions of under-replication could drive RPA exhaustion and replication catastrophe (Toledo et al., 2013) . Alternatively, given that ssDNA marks apoptotic cells and ssDNA induces apoptosis (Chen et al., 1997; Frankfurt et al., 1996; Gagna et al., 2000; Michiue et al., 2008; Nur et al., 2003) , the accumulation of an excessive amount of ssDNA could be the single driver of cell killing. Our findings further indicate that PARPi resistance involves gap suppression by either a block to fork elongation or by the acquisition of gap filling activity such as mediated by translesion synthesis (TLS). In support of this latter point, PARPi resistance in BRCA2 deficient cells is achieved by loss of CHD4 that elevates TLS (Guillemette et al., 2015) . Moreover, p21 is a TLS inhibitor (Avkin et al., 2006) and its loss lengthens tracts without gaps. Notably, 53BP1 loss uniquely rescues BRCA1 deficient cells and CHD4 loss uniquely rescues BRCA2 deficient cells (Bouwman et al., 2010; Bunting et al., 2010; Guillemette et al., 2015; Ray Chaudhuri et al., 2016) .
Thus, the mechanism of gap suppression is distinct in BRCA backgrounds for reasons that remain to be fully understood.
While we cannot exclude the possibility that eventual PARPi-induced fork degradation and/or breaks contribute to sensitizing BRCA deficient cells, we present a series of separation-of-function models that indicate a greater correlation between gap induction and therapy response than loss of either HR or FP. Moreover, if DSBs were the sensitizing lesion, logically HR proficient cells should repair PARPiinduced DSBs and show PARPi resistance. However, the HR proficient FA cell line is sensitive to PARPi (Wang et al., 2015) even when FP is also restored. These findings indicate that HR and FP are not sufficient to confer PARPi resistance if gaps exceed a toxicity threshold. Indeed, the rationale for limiting PARPi to HR defective cancers is already in question as recent clinical trials found significant clinical benefit across ovarian cancer patients regardless of BRCA status (Ledermann and Pujade-Lauraine, 2019). Moreover, our study indicates that to further improve PARPi progression free, overall survival or in maintenance therapy (Miller et al., 2019) , it will be critical to target gap suppression pathways. Collectively, these findings highlight the importance of considering ssDNA gaps as a critical biomarker and determinant of therapy response. Immunofluorescence for ssDNA. Cells were grown on coverslips in 10 μM CldU for 48 h before the indicated treatment in figures without CldU. After treatment, cells were washed with PBS and preextracted by 0.5% Triton X-100 made in phosphate-buffered saline (PBS) on ice. Cells were then fixed using 4% Formalin for 15 min at RT, and then permeabilized by 0.5% Triton X-100 in PBS again.
Permeabilized cells were then incubated with primary antibodies against CldU (Abcam 6326) at 37°C for 1h. Cells were washed and incubated with secondary antibodies (Alexa Fluor 594) for 1 h at room temperature. After washing, cover slips were mounted onto glass slides using Vectashield mounting medium containing DAPI (Vector Laboratories). Images were collected by fluorescence microscopy (Axioplan 2 and Axio Observer, Zeiss) at a constant exposure time in each experiment. Representative images were processed by ImageJ software. Mean intensities of ssDNA in each nucleus were measured with Cell Profiler software version 3.1.5 from Broad Institute.
DNA fiber assay and S1 nuclease analysis. These assays were performed as previously described (Peng et al., 2018) . Cells were labeled by sequential incorporation of two different nucleotide analogs, IdU and CldU, into nascent DNA strands for the indicated time and conditions. After nucleotide analogs were incorporated in vivo, the cells were collected, washed, spotted, and lysed on positively charged microscope slides by 7.5 mL spreading buffer for 8 min at room temperature. For experiments with the ssDNA-specific endonuclease S1, after the CldU pulse, cells were treated with CSK100 buffer for 10 min at room temperature, then incubated with S1 nuclease buffer with or without 20 U/mL S1 nuclease (Invitrogen, 18001-016) for 30 min at 37 C. The cells were then scraped in PBS + 0.1% BSA and centrifuged at 7,000 rpm for 5 min at 4 C. Cell pellets were resuspended at 1,500 cells/mL and lysed with lysis solution on slides. Individual DNA fibers were released and spread by tilting the slides at 45 degrees. After air-drying, fibers were fixed by 3:1 methanol/acetic acid at room temperature for 3 min. After air-drying again, fibers were rehydrated in PBS, denatured with 2.5 M HCl for 30 min, washed with PBS, and blocked with blocking buffer for 1 hr. Next, slides were incubated for 2.5 hr with primary antibodies for (IdU, Becton Dickinson 347580; CldU, Abcam 6326) diluted in blocking buffer, washed several times in PBS, and then incubated with secondary antibodies (IdU, goat anti-mouse, Alexa 488;
CldU, goat anti-rat, Alexa Fluor 594) in blocking buffer for 1 hr. After washing and air-drying, slides were mounted with Prolong (Invitrogen, P36930). Finally, visualization of green and/or red signals by fluorescence microscopy (Axioplan 2 imaging, Zeiss) provided information about the active replication directionality at the single-molecule level. 20180905+0918 RPE1 PARPi S1 nuclease S1 nuclease - 
